Trials / Recruiting
RecruitingNCT03844360
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,500 (estimated)
- Sponsor
- Wei Zhao · Academic / Other
- Sex
- All
- Age
- 1 Day – 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Detailed description
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | bortezomib was administered follow the doctor's advice. |
| DRUG | Eltrombopag | eltrombopag was administered follow the doctor's advice. |
| DRUG | Imatinib | imatinib was administered follow the doctor's advice. |
| DRUG | dasatinib | dasatinib was administered follow the doctor's advice. |
| DRUG | Pegaspargase | pegaspargase was administered follow the doctor's advice. |
| DRUG | Anti-Infective Drugs | anti-infective drugs was administered follow the doctor's advice. |
| DRUG | PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor | pegaspargase was administered follow the doctor's advice. |
Timeline
- Start date
- 2016-01-31
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2019-02-18
- Last updated
- 2025-03-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03844360. Inclusion in this directory is not an endorsement.